Trial met its primary objective with imeglimin observed to have a favorable safety and tolerability profile in patients with type 2 diabetes and chronic kidney disease stages 3b/4 Pharmacokinetics (PK)…
Read More
Poxel to receive upfront payment of $35 million (approximately €28 million), potential future development and regulatory milestone payments and sales-based payments of up to $600 million (approximately €486 million), and…